Profile data is unavailable for this security.
About the company
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.
- Revenue in USD (TTM)174.91m
- Net income in USD-190.42m
- Incorporated2017
- Employees355.00
- LocationDeciphera Pharmaceuticals Inc200 Smith StWALTHAM 02451-0099United StatesUSA
- Phone+1 (781) 209-6400
- Fax+1 (302) 655-5049
- Websitehttps://www.deciphera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vera Therapeutics Inc | 0.00 | -94.30m | 2.03bn | 55.00 | -- | 5.71 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Geron Corp | 520.00k | -201.40m | 2.07bn | 141.00 | -- | 5.94 | -- | 3,980.83 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 2.10bn | 186.00 | -- | 2.95 | -- | 26.46 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Myriad Genetics, Inc. | 774.20m | -234.60m | 2.11bn | 2.70k | -- | 2.77 | -- | 2.72 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.12bn | 1.76k | 14.94 | 3.15 | 10.55 | 3.13 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Novavax Inc | 996.61m | -398.71m | 2.13bn | 1.54k | -- | -- | -- | 2.13 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.15bn | 500.00 | -- | 5.35 | -- | 46.42 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.20bn | 624.00 | -- | 14.28 | 460.33 | 7.75 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.21bn | 355.00 | -- | 6.63 | -- | 12.61 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.23bn | 64.00 | -- | 3.40 | -- | 306.11 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.28bn | 226.00 | -- | 37.00 | -- | 24.79 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Fortrea Holdings Inc | 3.01bn | -102.40m | 2.30bn | 18.00k | -- | 1.43 | -- | 0.7641 | -1.15 | -1.38 | 33.80 | 17.92 | 0.7027 | -- | 3.10 | -- | -2.39 | -- | -2.89 | -- | 16.64 | -- | -3.41 | -- | -- | 0.0877 | 0.5019 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Vericel Corp | 207.78m | 451.00k | 2.33bn | 314.00 | 5,019.88 | 9.95 | 431.93 | 11.23 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.39bn | 160.00 | -- | 2.85 | -- | 394.25 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
Data as of May 23 2024. Currency figures normalised to Deciphera Pharmaceuticals Inc's reporting currency: US Dollar USD
37.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 5.90m | 7.18% |
| Redmile Group LLCas of 31 Mar 2024 | 5.30m | 6.45% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.71m | 5.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.47m | 5.45% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.10m | 3.77% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.61m | 1.96% |
| Polar Capital LLPas of 31 Mar 2024 | 1.50m | 1.83% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.45m | 1.77% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.30m | 1.58% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.25m | 1.53% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
